FDA approves Tecartus for r/r mantle cell lymphoma

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

Cancer survivorship in the United States now tops 18 million people. That is a lot of people walking around with a shared experience, and yet somehow we barely talk about what surviving cancer actually does to you.

April 24, 2026

Vol.52 No.16

By Edward Miskie

Cancer Policy

One year of reducing animal testing in drug development

FDA announced that it has achieved its first-year goals in implementing its roadmap to reduce animal testing in preclinical studies.

April 24, 2026

Vol.52 No.16

By Claire Marie Porter

Cancer Policy

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

The Centers for Medicare and Medicaid Services and FDA announced a new coverage pathway—called the Regulatory Alignment for Predictable and Immediate Device, or RAPID pathway—designed to expedite access to certain FDA-designated Class II and Class III Breakthrough devices for people with Medicare.

April 24, 2026

Vol.52 No.16

Drugs & Targets

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

FDA granted Fast Track designation to Debiopharm for the use of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123) for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer.

April 24, 2026

Vol.52 No.16

Podcast

No need for a speculum? A new era of HPV screening

FDA has cleared the first at-home self-collection kit for HPV screening, removing significant obstacles to cervical cancer detection.

April 22, 2026

Health Equity Regulatory News

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Boca Raton resident Gabriela Sanchez recently found herself stepping into a mobile outreach vehicle operated by Sylvester Comprehensive Cancer Center.

April 17, 2026

Vol.52 No.15

By Claire Marie Porter

FDA approves Tecartus for r/r mantle cell lymphoma

YOU MAY BE INTERESTED IN

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

One year of reducing animal testing in drug development

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

No need for a speculum? A new era of HPV screening

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line

Renew today!

Subscriber content

Never miss an issue!

Login

FDA approves Tecartus for r/r mantle cell lymphoma

YOU MAY BE INTERESTED IN

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

One year of reducing animal testing in drug development

FDA and CMS announce RAPID coverage pathway aimed at accelerating patient access to some Breakthrough medical devices

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

No need for a speculum? A new era of HPV screening

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line

Never miss an issue!

Login

Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line